Author:
Giordano Guido,Febbraro Antonio,Tomaselli Eugenio,Sarnicola Maria Lucia,Parcesepe Pietro,Parente Domenico,Forte Nicola,Fabozzi Alessio,Remo Andrea,Bonetti Andrea,Manfrin Erminia,Ghasemi Somayehsadat,Ceccarelli Michele,Cerulo Luigi,Bazzoni Flavia,Pancione Massimo
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Argiles G, Dienstmann R, Elez E, et al. Panitumumab: a summary of clinical development in colorectal cancer and future directions. Future Oncol. 2012;8(4):373–89.
2. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34.
3. Martinelli E, Troiani T, Morgillo F, Orditura M, De Vita F, Belli G, et al. Emerging VEGF receptor inhibitors for colorectal cancer. Expert Opin Emerg Drugs. 2013;18:25–37.
4. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12.
5. Xu JM, Liu XJ, Ge FJ, Lin L, Wang Y, Sharma MR, et al. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. J Exp Clin Cancer Res. 2014;10:33–104.
Cited by
56 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献